Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Friday, Marketbeat reports. They currently have a $22.00 price target on the biotechnology company’s stock, down from their previous price target of $43.00. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 64.18% from the stock’s current price.
ATRA has been the subject of a number of other reports. Citigroup set a $14.00 price target on shares of Atara Biotherapeutics and gave the company a “hold” rating in a report on Monday, August 12th. ValuEngine raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, September 13th. Finally, Goldman Sachs Group downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their price target for the company from $14.00 to $9.00 in a report on Friday, September 27th. Three analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.89.
ATRA traded down $0.12 on Friday, reaching $13.40. The company had a trading volume of 545,300 shares, compared to its average volume of 677,343. The company has a fifty day moving average of $13.21 and a 200-day moving average of $18.25. The company has a market capitalization of $679.50 million, a P/E ratio of -2.54 and a beta of 2.04. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics has a one year low of $10.38 and a one year high of $43.94.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.40) by $0.09. Research analysts predict that Atara Biotherapeutics will post -5.71 EPS for the current year.
In other Atara Biotherapeutics news, insider Joe Newell sold 3,500 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the completion of the sale, the insider now directly owns 57,998 shares of the company’s stock, valued at $783,552.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Atara Biotherapeutics by 59.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,010 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Atara Biotherapeutics in the third quarter worth approximately $40,000. Aperio Group LLC purchased a new stake in shares of Atara Biotherapeutics in the second quarter worth approximately $63,000. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics in the first quarter worth approximately $284,000. Finally, Bank of Montreal Can lifted its position in shares of Atara Biotherapeutics by 81.1% in the second quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 3,723 shares in the last quarter. 91.98% of the stock is owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: Swap
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.